闭系统定量实时聚合酶链反应检测的程序性死亡配体1与程序性死亡配体2 mRNA与免疫治疗肺癌的结局相关并具高阴性预测值
本研究采用闭系统定量实时逆转录聚合酶链反应(GeneXpert)检测122例晚期非小细胞肺癌(NSCLC)患者免疫检查点抑制剂(ICI)治疗前组织中CD274(PD-L1)、PDCD1LG2(PD-L2)、CD8A和IRF1四个免疫基因与ICI疗效的关联。结果显示PD-L1和PD-L2 mRNA高表达与24个月长期获益及总生存改善相关,低PD-L1 mRNA对缺乏长期获益的阴性预测值为0.92。
要点
- PD-L1与PD-L2 mRNA高表达均与24个月长期获益相关(p=0.047)。
- PD-L1 mRNA低表达对无长期获益的阴性预测值为0.92。
- PD-L1及PD-L2 mRNA水平在KRAS突变患者中更高。
核心结论
- 在低分期患者中进一步验证该检测后,评估PD-L1 mRNA而非蛋白可能成为确定哪些低分期患者不应在辅助治疗中接受ICI的方法。
- 该方法也可能成为晚期患者治疗选择的有用客观方法。
研究设计与样本
- 回顾性队列研究,纳入122例晚期NSCLC患者,于ICI治疗前采集组织,经大体显微切割后使用GeneXpert系统进行仅限研究用的定量实时逆转录聚合酶链反应检测。
主要发现
- PD-L1和PD-L2 mRNA高表达均与24个月长期获益相关(两者p=0.047)。
- PD-L1 mRNA高表达与总生存相关(p=0.048),PD-L2 mRNA高表达与总生存相关(p=0.049)。
- PD-L1和PD-L2 mRNA水平在KRAS突变患者中更高。
- 低PD-L1 mRNA水平对缺乏长期获益的阴性预测值为0.92。
关键数值与推荐
- PD-L1 mRNA高表达与24个月长期获益相关(p=0.047)。
- PD-L2 mRNA高表达与24个月长期获益相关(p=0.047)。
- PD-L1 mRNA高表达与总生存相关(p=0.048)。
- PD-L2 mRNA高表达与总生存相关(p=0.049)。
- 低PD-L1 mRNA水平对缺乏长期获益的阴性预测值为0.92。
局限性
- 原文指出该检测需在低分期患者中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become standard of care in lung cancer management, but only a relatively small percentage of patients treated respond. Current predictive biomarkers, including immunohistochemical detection of programmed death-ligand 1 (PD-L1), are insufficient for determining who will respond or, more importantly in the adjuvant setting, who will not respond to ICI therapy. Here, we investigate an alternative method of assessment of PD-L1 to predict nonresponse. METHODS: This study uses a research use only quantitative real-time reverse transcription polymerase chain reaction assay on the GeneXpert system, to test for the association between four target immune genes, CD274 (PD-L1), PDCD1LG2 (programmed death-ligand 2 [PD-L2]), CD8A, and IRF1, and response to ICI therapy. Tissues were collected from 122 patients with advanced NSCLC before ICI therapy in a retrospective cohort, macrodissected, and analyzed using the GeneXpert. RESULTS: Both high PD-L1 and PD-L2 mRNA expression levels were associated with improved long-term benefit at 24 months (p = 0.047 for both PD-L1 and PD-L2) and overall survival (PD-L1, p = 0.048; PD-L2, p = 0.049). Both PD-L1 and PD-L2 mRNA levels were higher in patients with KRAS mutations. Most importantly, low PD-L1 mRNA level had a high negative predictive value of 0.92 for absence of long-term benefit. CONCLUSIONS: With further validation of this assay in low-stage patients, an assessment of PD-L1 mRNA rather than protein, could be a method to determine which low-stage patients that should not be treated with ICIs in the adjuvant setting. This approach may also be a useful objective method for selecting patients for treatment in the advanced setting.
引用
- Fernandez AI, Gavrielatou N, McCann L, et al. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. J Thorac Oncol. 2022. PMID: 35764237. doi:10.1016/j.jtho.2022.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。